Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals, Inc. (CRNX) completed a merger in which it became a wholly owned subsidiary of Vertex Pharmaceuticals. At the September 1, 2026 effective time, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 in cash per share.
Director Wendell Wierenga reported only merger-related equity cancellations and cash-outs. 116,146 shares of common stock were canceled for the $85.00 cash consideration, and 5,925 restricted stock units became fully vested and were converted into cash at the same $85.00 per-share amount, less tax withholding.
Multiple tranches of stock options were also canceled. Each vested option with an exercise price below $85.00 was converted into the right to receive cash equal to the difference between $85.00 and its exercise price (for example, options with a $23.24 exercise price yielded $61.76 per option). Options with exercise prices at or above $85.00 were canceled for no consideration. These are issuer-related merger settlements, not open‑market trades.
Crinetics Pharmaceuticals, Inc. (CRNX) director Vivaldi Coelho Rogerio reported issuer-related dispositions on September 1, 2026 in connection with Crinetics’ merger into a wholly owned subsidiary of Vertex Pharmaceuticals. At the merger’s effective time, each Crinetics common share was canceled and converted into the right to receive $85.00 in cash per share, subject to tax withholding. The filing shows cancellation of common stock, restricted stock units, and stock options, which were converted into cash equal to the merger consideration (for shares and RSUs) or, for in-the-money options, the difference between the $85.00 merger consideration and the option exercise price, with underwater options canceled for no consideration.
Crinetics Pharmaceuticals, Inc. (CRNX) reports that director Stephanie Okey’s equity awards were canceled in connection with the merger under which Vertex Pharmaceuticals acquired Crinetics. Effective September 1, 2026, each share of Crinetics common stock was converted into the right to receive $85.00 in cash, and Ms. Okey’s outstanding restricted stock units and stock options were canceled and converted into cash rights based on this merger consideration, less applicable exercise prices and tax withholdings. The Form 4 reflects these cancellations as dispositions to the issuer rather than open-market trades.
Crinetics Pharmaceuticals, Inc. (CRNX) director Weston Nichols reported the treatment of his equity awards in connection with the merger under which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals. At the September 1, 2026 effective time, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash. Nichols’ restricted stock units became fully vested immediately before closing, then were canceled and converted into cash equal to the $85.00 merger consideration per unit, less applicable tax withholding. His outstanding stock options were also canceled: options with exercise prices below $85.00 were converted into cash equal to the difference between $85.00 and the exercise price per option share (as reflected in Column 8 of the option rows), while options with exercise prices at or above $85.00 were canceled for no consideration. All transactions are coded as dispositions to the issuer reflecting this merger-driven cash-out rather than open-market trading.
Crinetics Pharmaceuticals, Inc. (CRNX) completed a merger with Vertex Pharmaceuticals effective September 1, 2026, in which each Crinetics common share was canceled and converted into the right to receive $85.00 in cash per share. Director Matthew K. Fust reported automatic, merger-related dispositions of 22,836 common shares and 5,925 RSU-equivalent shares, plus five stock option grants covering 52,172 shares. In-the-money options were canceled and converted into cash equal to $85.00 minus the applicable exercise price per option share, while any options with exercise prices at or above $85.00 were canceled for no consideration. These were structured cancellations to issuer in the merger, not open-market trades.
Crinetics Pharmaceuticals, Inc. (CRNX) director Caren Deardorf reported transactions triggered by the closing of the merger in which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals. At the September 1, 2026 effective time, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash, subject to tax withholding. Deardorf reported 16,300 shares of common stock and 5,925 shares underlying restricted stock units being canceled and converted into cash rights at this merger consideration. In addition, multiple stock option grants were canceled; options with exercise prices below the $85.00 merger consideration were converted into cash equal to the difference between $85.00 and the option’s exercise price per share, while options with exercise prices at or above $85.00 were canceled for no consideration.
Crinetics Pharmaceuticals, Inc. (CRNX) completed a merger under which it became a wholly owned subsidiary of Vertex Pharmaceuticals, with each Crinetics common share converted into the right to receive $85.00 in cash at the September 1, 2026 effective time. Director Camille L. Bedrosian reported disposition to the issuer of common stock and equity awards in connection with this closing. The filing shows cancellation-for-cash of multiple tranches of stock options, each covering specified numbers of shares at exercise prices below $85.00, and the cash-out of restricted stock units that first vested in full and then converted into cash at the same $85.00 per-share Merger Consideration, less applicable tax withholding.
Crinetics Pharmaceuticals, Inc. (CRNX) disclosed that Chief Commercial Officer Isabel Kalofonos reported merger-related dispositions effective September 1, 2026. In connection with the merger of Crinetics into a wholly owned subsidiary of Vertex Pharmaceuticals, each share of Crinetics common stock was canceled and converted into the right to receive $85.00 per share in cash, subject to tax withholding. The filing reports cancellation of common shares, restricted stock units and stock options, which were converted into cash rights based on the Merger Consideration or, for certain out-of-the-money options, canceled for no consideration.
Crinetics Pharmaceuticals, Inc. (CRNX) reports that Chief Scientific Officer Stephen F. Betz had his equity interests canceled and settled in cash in connection with the merger under which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals Incorporated. On September 1, 2026, all common shares and restricted stock units were converted into the right to receive $85.00 per share in cash, subject to tax withholding. On the same date, multiple outstanding stock options were canceled: options with exercise prices below $85.00 were converted into cash equal to the $85.00 merger consideration minus the applicable exercise price per option share, while options with exercise prices at or above $85.00 were canceled for no consideration. A total of 13 disposition-to-issuer transactions were reported, reflecting this merger-driven cancellation and cash-out of Betz’s equity awards.